User login
Developments in metastatic breast cancer (MBC) were reported at the European Society for Medical Oncology (ESMO) 2023 Congress and are discussed by Dr Ann Partridge of Dana-Farber Cancer Institute.
To begin, Dr Partridge highlights a late-breaking abstract showing that use of the antibody-drug conjugate (ADC) datopotamab deruxtecan in hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2-) MBC results in improved progression-free survival (PFS) compared with chemotherapy.
Next, Dr Partridge turns to two studies on another ADC, trastuzumab deruxtecan (T-DXd), in MBC. The first study showed positive PFS and overall survival results among patients with either estrogen receptor–positive (ER+)/HER2-low or triple-negative/HER2-low breast cancer. The second T-DXd study examined the ADC's impact on brain metastases in patients with HER2+ disease and reported favorable results.
She then highlights promising phase 2 results for a novel agent called OP-1250, or palazestrant, studied in patients with ER+/HER2- MBC.
Finally, Dr Partridge points to a study of a supportive-care program called MOATT, designed for patients on oral MBC therapy, which aims to improve home management. Compared with local standard of care, patients in the program show higher rates of persistence in therapy management and, importantly, concomitant improvements in PFS.
--
Ann H. Partridge, MD, Professor of Medicine, Harvard Medical School; Vice Chair of Clinical Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Ann H. Partridge, MD, MPH, has disclosed no relevant financial relationships.
Developments in metastatic breast cancer (MBC) were reported at the European Society for Medical Oncology (ESMO) 2023 Congress and are discussed by Dr Ann Partridge of Dana-Farber Cancer Institute.
To begin, Dr Partridge highlights a late-breaking abstract showing that use of the antibody-drug conjugate (ADC) datopotamab deruxtecan in hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2-) MBC results in improved progression-free survival (PFS) compared with chemotherapy.
Next, Dr Partridge turns to two studies on another ADC, trastuzumab deruxtecan (T-DXd), in MBC. The first study showed positive PFS and overall survival results among patients with either estrogen receptor–positive (ER+)/HER2-low or triple-negative/HER2-low breast cancer. The second T-DXd study examined the ADC's impact on brain metastases in patients with HER2+ disease and reported favorable results.
She then highlights promising phase 2 results for a novel agent called OP-1250, or palazestrant, studied in patients with ER+/HER2- MBC.
Finally, Dr Partridge points to a study of a supportive-care program called MOATT, designed for patients on oral MBC therapy, which aims to improve home management. Compared with local standard of care, patients in the program show higher rates of persistence in therapy management and, importantly, concomitant improvements in PFS.
--
Ann H. Partridge, MD, Professor of Medicine, Harvard Medical School; Vice Chair of Clinical Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Ann H. Partridge, MD, MPH, has disclosed no relevant financial relationships.
Developments in metastatic breast cancer (MBC) were reported at the European Society for Medical Oncology (ESMO) 2023 Congress and are discussed by Dr Ann Partridge of Dana-Farber Cancer Institute.
To begin, Dr Partridge highlights a late-breaking abstract showing that use of the antibody-drug conjugate (ADC) datopotamab deruxtecan in hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2-) MBC results in improved progression-free survival (PFS) compared with chemotherapy.
Next, Dr Partridge turns to two studies on another ADC, trastuzumab deruxtecan (T-DXd), in MBC. The first study showed positive PFS and overall survival results among patients with either estrogen receptor–positive (ER+)/HER2-low or triple-negative/HER2-low breast cancer. The second T-DXd study examined the ADC's impact on brain metastases in patients with HER2+ disease and reported favorable results.
She then highlights promising phase 2 results for a novel agent called OP-1250, or palazestrant, studied in patients with ER+/HER2- MBC.
Finally, Dr Partridge points to a study of a supportive-care program called MOATT, designed for patients on oral MBC therapy, which aims to improve home management. Compared with local standard of care, patients in the program show higher rates of persistence in therapy management and, importantly, concomitant improvements in PFS.
--
Ann H. Partridge, MD, Professor of Medicine, Harvard Medical School; Vice Chair of Clinical Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Ann H. Partridge, MD, MPH, has disclosed no relevant financial relationships.
